
www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800


Recombinant SARS-Cov-2 Spike RBD protein (E417N, E484K, N501Y), His

Catalog Number:	bs-41449P
Concentration:	＞0.5 mg/ml
AA Seq:	319-541/1273
Predicted MW:	30
Detected MW:	36 kDa
Tags:	His
Activity:	Yes
Endotoxin:	Not analyzed
Purity:	>90% as determined by SDS-PAGE
Purification:	AC
Form:	Lyophilized or Liquid
Storage:	PBS (pH7.4). Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.
Background:	The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.


VALIDATION IMAGES



Measured by its binding ability in a functional ELISA. Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2μg/ml (100ul/Well) can bind SARS-CoV-2 Spike RBD (K417N, E484K, N501Y), His Tag (Cat: bs-41449P) , the EC50 is 15.63ng/ml.




The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.